Photocure announces new Cevira patent in Europe

OSLO: Photocure ASA announced that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira device in Europe until 2034.

Cevira is a photodynamic drug-device combination product under development for non-surgical treatment of high-grade cervical dysplasia. In July 2019, Photocure announced that it had entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a world-wide license to develop and commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. In July 2020, Asieris received China NMPA’s approval to start a global Phase III clinical trial for APL-1702 (Cevira).

The EP 2983780 patent covering the commercial Cevira device in Europe, will expire 09 April 2034.

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO).

www.photocure.com